B-intervention	0	10	Lisinopril
I-intervention	11	13	or
I-intervention	14	19	Coreg
I-intervention	20	22	CR
O	23	25	in
O	26	34	reducing
B-condition	35	49	cardiotoxicity
O	50	52	in
B-eligibility	53	58	women
I-eligibility	59	63	with
I-eligibility	64	70	breast
I-eligibility	71	77	cancer
I-eligibility	78	87	receiving
I-eligibility	88	99	trastuzumab
O	99	100	:
O	101	102	A
O	103	112	rationale
O	113	116	and
O	117	123	design
O	124	126	of
O	127	128	a
O	129	139	randomized
O	140	148	clinical
O	149	154	trial
O	154	155	.

O	156	167	Trastuzumab
O	168	169	(
O	169	172	TZB
O	172	173	)
O	174	176	is
O	177	179	an
O	180	191	established
O	192	199	therapy
O	200	203	for
O	204	208	HER2
O	208	209	-
O	209	217	positive
O	218	224	breast
O	225	231	cancer
O	231	232	.

O	233	236	The
O	237	240	use
O	241	243	of
O	244	247	TZB
O	248	250	is
O	251	259	commonly
O	260	270	associated
O	271	275	with
O	276	290	cardiotoxicity
O	291	302	manifesting
O	303	305	as
O	306	318	asymptomatic
O	319	327	decrease
O	328	330	in
O	331	335	left
O	336	347	ventricular
O	348	356	ejection
O	357	365	fraction
O	366	367	(
O	367	371	LVEF
O	371	372	)
O	373	375	or
O	376	381	overt
O	382	387	heart
O	388	395	failure
O	395	396	.

O	397	404	Several
O	405	412	studies
O	413	425	demonstrated
O	426	435	favorable
O	436	443	effects
O	444	446	of
O	447	458	angiotensin
O	458	459	-
O	459	469	converting
O	470	476	enzyme
O	477	478	(
O	478	481	ACE
O	481	482	)
O	483	493	inhibitors
O	494	497	and
O	498	499	β
O	499	500	-
O	500	508	blockers
O	509	510	(
O	510	513	BBs
O	513	514	)
O	515	517	in
O	518	521	the
O	522	532	prevention
O	533	535	of
O	536	548	chemotherapy
O	548	549	-
O	549	556	induced
O	557	571	cardiotoxicity
O	571	572	.

O	573	575	We
O	576	587	hypothesize
O	588	592	that
O	593	601	patients
O	601	602	,
O	603	613	randomized
O	614	616	to
O	617	624	receive
O	625	627	an
O	628	631	ACE
O	632	641	inhibitor
O	642	644	or
O	645	646	a
O	647	649	BB
O	650	656	during
O	657	668	trastuzumab
O	669	676	therapy
O	677	680	for
O	681	687	breast
O	688	694	cancer
O	694	695	,
O	696	700	will
O	701	709	maintain
O	710	711	a
O	712	718	higher
O	719	723	LVEF
O	724	728	than
O	729	737	patients
O	738	748	randomized
O	749	751	to
O	752	759	placebo
O	759	760	.

O	761	763	We
O	764	772	designed
O	773	774	a
O	775	786	prospective
O	786	787	,
O	788	799	multicenter
O	799	800	,
O	801	811	randomized
O	811	812	,
O	813	818	phase
O	819	821	II
O	822	829	placebo
O	829	830	-
O	830	840	controlled
O	841	849	clinical
O	850	855	trial
O	856	858	to
O	859	867	evaluate
O	868	871	the
O	872	879	effects
O	880	882	of
O	883	885	an
O	886	889	ACE
O	890	899	inhibitor
O	900	901	(
O	901	911	lisinopril
O	911	912	)
O	913	916	and
O	917	918	a
O	919	921	BB
O	922	923	(
O	923	933	carvedilol
O	934	943	phosphate
O	943	944	-
O	944	952	extended
O	953	960	release
O	960	961	)
O	962	964	on
O	965	979	cardiotoxicity
O	980	982	in
B-eligibility	983	991	patients
I-eligibility	992	996	with
I-eligibility	997	1003	breast
I-eligibility	1004	1010	cancer
I-eligibility	1011	1014	who
I-eligibility	1015	1018	are
I-eligibility	1019	1028	receiving
I-eligibility	1029	1037	adjuvant
I-eligibility	1038	1040	or
I-eligibility	1041	1052	neoadjuvant
I-eligibility	1053	1056	TZB
I-eligibility	1057	1064	therapy
O	1064	1065	.

O	1066	1069	The
O	1070	1077	primary
O	1078	1088	objectives
O	1089	1096	include
O	1097	1098	(
O	1098	1099	1
O	1099	1100	)
B-outcome-Measure	1101	1111	comparison
I-outcome-Measure	1112	1114	of
I-outcome-Measure	1115	1124	incidence
I-outcome-Measure	1125	1127	of
I-outcome-Measure	1128	1142	cardiotoxicity
O	1143	1146	and
O	1147	1148	(
O	1148	1149	2
O	1149	1150	)
B-outcome-Measure	1151	1161	comparison
I-outcome-Measure	1162	1164	of
I-outcome-Measure	1165	1169	LVEF
O	1170	1172	as
O	1173	1174	a
O	1175	1185	continuous
O	1186	1194	variable
O	1195	1197	in
O	1198	1205	between
O	1206	1209	the
O	1210	1214	arms
O	1214	1215	.

O	1216	1230	Cardiotoxicity
O	1231	1234	was
O	1235	1242	defined
O	1243	1245	as
O	1246	1248	an
O	1249	1257	absolute
O	1258	1266	decrease
O	1267	1269	in
O	1270	1274	LVEF
O	1275	1279	from
O	1280	1288	baseline
O	1289	1291	of
O	1292	1293	≥
O	1293	1295	10
O	1295	1296	%
O	1297	1299	at
O	1300	1306	follow
O	1306	1307	-
O	1307	1309	up
O	1310	1312	or
O	1313	1315	an
O	1316	1324	absolute
O	1325	1333	decrease
O	1334	1336	of
O	1337	1338	≥
O	1338	1339	5
O	1339	1340	%
O	1341	1343	in
O	1344	1348	LVEF
O	1349	1353	from
O	1354	1362	baseline
O	1363	1366	for
O	1367	1378	individuals
O	1379	1383	with
O	1384	1385	<
O	1385	1387	50
O	1387	1388	%
O	1389	1393	LVEF
O	1394	1396	at
O	1397	1403	follow
O	1403	1404	-
O	1404	1406	up
O	1406	1407	.

O	1408	1411	The
O	1412	1418	target
O	1419	1426	accrual
O	1427	1429	is
B-total-participants	1430	1433	468
O	1434	1446	participants
O	1446	1447	,
O	1448	1460	representing
O	1461	1469	patients
O	1470	1474	both
O	1475	1479	with
O	1480	1483	and
O	1484	1491	without
O	1492	1505	anthracycline
O	1506	1514	exposure
O	1514	1515	.

O	1516	1519	The
O	1520	1530	enrollment
O	1531	1533	is
O	1534	1543	completed
O	1543	1544	.

O	1545	1548	The
O	1549	1554	trial
O	1555	1557	is
O	1558	1560	co
O	1560	1561	-
O	1561	1570	sponsored
O	1571	1573	by
O	1574	1584	University
O	1585	1587	of
O	1588	1593	South
O	1594	1601	Florida
O	1602	1605	and
O	1606	1614	National
O	1615	1621	Cancer
O	1622	1631	Institute
O	1631	1632	.

O	1633	1636	The
O	1637	1641	LVEF
O	1642	1644	is
O	1645	1650	being
O	1651	1660	evaluated
O	1661	1663	by
O	1664	1680	echocardiography
O	1681	1683	or
O	1684	1694	multigated
O	1695	1706	acquisition
O	1707	1711	scan
O	1711	1712	.

O	1713	1715	If
O	1716	1718	we
O	1719	1722	can
O	1723	1734	demonstrate
O	1735	1739	that
O	1740	1743	the
O	1744	1747	use
O	1748	1750	of
O	1751	1753	an
O	1754	1757	ACE
O	1758	1767	inhibitor
O	1768	1770	or
O	1771	1772	a
O	1773	1775	BB
O	1776	1779	can
O	1780	1786	reduce
O	1787	1790	the
O	1791	1797	degree
O	1798	1800	of
O	1801	1804	TZB
O	1804	1805	-
O	1805	1812	induced
O	1813	1827	cardiotoxicity
O	1827	1828	,
O	1829	1831	it
O	1832	1834	is
O	1835	1840	hoped
O	1841	1845	that
O	1846	1854	patients
O	1855	1859	will
O	1860	1867	receive
O	1868	1876	complete
O	1877	1880	and
O	1881	1894	uninterrupted
O	1895	1898	TZB
O	1899	1906	therapy
O	1907	1910	for
O	1911	1917	breast
O	1918	1924	cancer
O	1925	1932	without
O	1933	1945	compromising
O	1946	1953	cardiac
O	1954	1962	function
O	1962	1963	.
